4-Acetylantrocamol LT3, a New Ubiquinone from Antrodia cinnamomea, Inhibits Hepatocellular Carcinoma HepG2 Cell Growth by Targeting YAP/TAZ, mTOR, and WNT/β-Catenin Signaling.

The American Journal of Chinese Medicine
Yen-Lin ChenShih-Yu Lee

Abstract

4-acetylantrocamol LT3 (4AALT3), a new ubiquinone from the mycelium of Antrodia cinnamomea (Polyporaceae), has been recently shown to possess anticancer activity. However, the detailed mechanisms of such action remain unclear. In this study, the molecular mechanisms of 4AALT3 on hepatocellular carcinoma cells (HCC) were investigated. Human hepatocellular carcinoma cell line HepG2 cells were treated with concentrations of 4AALT3. Cell viability, colony formation, and the underlying mechanisms were then analyzed by CCK-8, colony formation, qPCR, and Western blotting assays. We found that 4AALT3 significantly decreased cell viability and colony formation in a dose-dependent manner. Accordingly, 4AALT3 significantly decreased protein levels of cyclin B, E1, D1, and D3, thereby facilitating cell cycle arrest. In addition, 4AALT3 significantly suppressed the nuclear localization of Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ), mammalian target of rapamycin (mTOR), and WNT/[Formula: see text]-catenin signaling pathways, all of which are well-known signaling pathways that contribute to the malignant properties of HCC. These effects are associated with activation of 5' AMP-activated protein kina...Continue Reading

References

Jun 23, 1997·FEBS Letters·N Pullen, G Thomas
Feb 19, 2005·Science·D D SarbassovDavid M Sabatini
Apr 15, 2006·The Journal of Physiology·Hiroyuki MotoshimaEiichi Araki
Feb 27, 2007·Journal of Hepatology·David SemelaJean-François Dufour
Jul 28, 2007·The Journal of Biological Chemistry·Mete ErdoganRoy Zent
Apr 12, 2008·Current Opinion in Clinical Nutrition and Metabolic Care·Ho-Jin KohLaurie J Goodyear
Oct 1, 2008·Cancer Letters·Ka Ho TamRonnie T P Poon
Oct 31, 2008·Nature Reviews. Molecular Cell Biology·Guido Kroemer, Beth Levine
Jan 27, 2009·Cellular Signalling·Regan M Memmott, Phillip A Dennis
Feb 6, 2009·Expert Review of Anticancer Therapy·Gerhard Treiber
Aug 19, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Madamanchi Geethangili, Yew-Min Tzeng
Jan 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Li LuRandy L Johnson
Feb 23, 2013·Genes & Development·Fa-Xing Yu, Kun-Liang Guan
Mar 8, 2013·Nature Reviews. Cancer·Kieran F HarveyDavid M Thomas
Jun 13, 2013·Molecular and Cellular Biochemistry·Yongpeng WeiJunhua Lu
Aug 15, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Longyi ZhengHongyang Wang
Dec 7, 2013·Journal of Hepatology·Matthias S MatterSnorri S Thorgeirsson
May 16, 2014·EMBO Reports·Jung-Soon MoKun-Liang Guan
Jul 11, 2014·Journal of Hepatology·Andrea PerraAmedeo Columbano
Aug 28, 2014·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Xudong HuangXinhua Lin
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
May 1, 2015·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Shih-Yu LeeTsu-Chung Chang
Dec 4, 2015·Drug Discoveries & Therapeutics·Shaohua Ge, Dingzhi Huang
Sep 13, 2016·Oncogene·T ZhanM Boutros
Sep 14, 2017·International Journal of Oncology·Caijie LuMingyi Li
Jan 5, 2018·The American Journal of Chinese Medicine·Kuen-Tze LinShih-Yu Lee
Jul 10, 2018·Journal of Hepatocellular Carcinoma·Ahmed M KhalafKhaled M Elsayes
Sep 27, 2018·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Samir F ZohnyHani Choudhry

❮ Previous
Next ❯

Citations

Jan 18, 2021·Free Radical Biology & Medicine·Guillermo López-Lluch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms